Related Experiment Video
Updated: Jan 27, 2026

Isolation and Chemical Characterization of Lipid A from Gram-negative Bacteria
Published on: September 16, 2013
Broad Bactericidal Activity of the Myoviridae Bacteriophage Lysins LysAm24, LysECD7, and LysSi3 against Gram-Negative
Nataliia P Antonova1,2, Daria V Vasina3, Anastasiya M Lendel4
1N.F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia. northernnatalia@gmail.com.
Abstract:
The extremely rapid spread of multiple-antibiotic resistance among Gram-negative pathogens threatens to move humankind into the so-called "post-antibiotic era" in which the most efficient and safe antibiotics will not work. Bacteriophage lysins represent promising alternatives to antibiotics, as they are capable of digesting bacterial cell wall peptidoglycans to promote their osmotic lysis. However, relatively little is known regarding the spectrum of lysin bactericidal activity against Gram-negative bacteria. In this study, we present the results of in vitro activity assays of three putative and newly cloned Myoviridae bacteriophage endolysins (LysAm24, LysECD7, and LysSi3). The chosen proteins represent lysins with diverse domain organization (single-domain vs. two-domain) and different predicted mechanisms of action (lysozyme vs. peptidase). The enzymes were purified, and their properties were characterized. The enzymes were tested against a panel of Gram-negative clinical bacterial isolates comprising all Gram-negative representatives of the ESKAPE group. Despite exhibiting different structural organizations, all of the assayed lysins were shown to be capable of lysing Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and Salmonella typhi strains. Less than 50 μg/mL was enough to eradicate growing cells over more than five orders of magnitude. Thus, LysAm24, LysECD7, and LysSi3 represent promising therapeutic agents for drug development.
Insights
Bacteriophage lysins show potent activity against drug-resistant Gram-negative bacteria. These novel enzymes, LysAm24, LysECD7, and LysSi3, effectively kill ESKAPE pathogens, offering new hope against antibiotic resistance.
Area of Science:
- Microbiology
- Molecular Biology
- Biochemistry
Background:
- The rise of multidrug-resistant Gram-negative pathogens poses a significant global health threat, potentially leading to a post-antibiotic era.
- Bacteriophage lysins, enzymes that degrade bacterial cell walls, are explored as potential alternatives to conventional antibiotics.
- Limited data exists on the efficacy of bacteriophage lysins against a broad spectrum of Gram-negative bacteria.
Purpose of the Study:
- To evaluate the in vitro bactericidal activity of three newly characterized bacteriophage endolysins (LysAm24, LysECD7, and LysSi3) against Gram-negative clinical isolates.
- To investigate the potential of these lysins as therapeutic agents in combating antibiotic-resistant infections.
Main Methods:
- Cloning and purification of three putative Myoviridae bacteriophage endolysins: LysAm24, LysECD7, and LysSi3.
- Characterization of the purified lysins' enzymatic properties.
- In vitro activity assays against a panel of Gram-negative clinical isolates, including ESKAPE pathogens (Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Enterococcus faecium, and Staphylococcus aureus) and Salmonella typhi.
Main Results:
- All three tested lysins (LysAm24, LysECD7, and LysSi3) demonstrated broad-spectrum lytic activity against Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and Salmonella typhi.
- Effective eradication of bacterial cells was achieved at concentrations below 50 μg/mL, reducing bacterial populations by over five orders of magnitude.
- Lysins with diverse domain organizations and predicted mechanisms of action exhibited comparable efficacy.
Conclusions:
- LysAm24, LysECD7, and LysSi3 are effective bactericidal agents against key Gram-negative pathogens.
- These bacteriophage endolysins represent promising candidates for the development of novel antimicrobial therapies to combat multidrug-resistant infections.
- Further research into these lysins could lead to new strategies to overcome the challenge of the declining antibiotic arsenal.
Related Concept Videos
Gram-negative Bacterial Protein Secretion Systems
Lysogenic Cycle of Bacteriophages
Lytic Cycle of Bacteriophages
DNA Bacteriophages
Negative Regulator Molecules
Positive, Negative, and Zero Work

